- Home
- Our Investigators
- Jamie L. Lesnock, MD
Jamie L. Lesnock, MD
Associate Professor, Obstetrics, Gynecology & Reproductive Sciences, University of Pittsburgh; Division of Gynecologic Oncology, UPMC Magee-Womens Hospital
I have an interest in cost-effectiveness analyses across the spectrum of gynecologic oncology, as well as evaluating clinical outcomes via institutional or large database sets to answer questions not readily evaluable with prospective trials and translational research.
Jamie L. Lesnock, MD
Research in Brief
Dr. Lesnock aims to ensure that cancer care for women—especially surgical and treatment protocols—is not only clinically effective but also economically sustainable, allowing better allocation of resources and improved patient outcomes.
Current Projects
Detection of Lynch Syndrome in Benign and Pre-invasive Endometrial Cancer Lesions
- Magee Women’s Cancer Research and Education Funding Committee Award, 2023-2025
Evaluating the Relationship between Fallopian Tube Lesions and Endometrial Cancer
- Magee Women’s Cancer Research and Education Funding Committee Award, 2023-2025
Selected Publications
- Lesnock JL, Darcy KM, Tian C, DeLoia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC. BRCA1 Expression and Improved Survival in Ovarian Cancer Patients Treated with Intraperitoneal Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study. Br J Cancer, 2013; 108(6):1231-7. PMID: 23462720
- Lesnock JL, Arnold RM, Meyn LA, Buss MK, Quimper M, Krivak TC, Edwards RP, Chang JC. Palliative Care Education in Gynecologic Oncology: A Survey of the Fellows. Gynecol Oncol, 2013; 130 (3): 431-5. PMID: 23694719
- Gaillard S, Lacchetti C, Armstrong DK, Cliby WA, Edelson MI, Garcia AA, Ghebre RG, Gressel GM, Lesnock JL, Meyer LA, Moore KN, O'Cearbhaill RE, Olawaiye AB, Salani R, Sparacio D, van Driel WJ, Tew WP: Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. Journal of Clinical Oncology 0, JCO-24-02589. DOI:10.1200/JCO-24-02589
- Orellana TJ, Kim H, Beriwal S, Taylor SE, Smith KJ, Lesnock JL. Cost-effectiveness analysis of tumor molecular testing in stage III endometrial cancer. Gynecol Oncol, 2023 Jun; 173:81-87. Doi: 10.1016/j.ygyno.2023.04.010. PMID: 37105061
- Bell S, Orellana T, Garrett A, Smith K, Kim H, Rosiello A, Rush S, Berger J, Lesnock J. Prophylactic anticoagulation after minimally invasive hysterectomy for endometrial cancer: a cost-effectiveness analysis. Int J Gynecol Cancer. 2023 Dec 4;33(12):1875-1881. doi: 10.1136/ijgc-2023-004922 .PMID: 37903564
For more publications, visit PubMed.